A new injectable drug can further knock down cholesterol levels in people who take cholesterol-busting statin medications, according to the results of a global trial.
People taking the new therapy alongside statins enjoyed a 63 - 75% decrease in their "bad" (LDL) cholesterol levels, on top of the reduction caused by the traditional statin medications. This drug enhances the body's natural way of reducing LDL levels in the bloodstream. Cells primarily located in the liver contain receptors that target LDL cholesterol and remove it from the bloodstream. But the liver also produces a regulatory protein called PCSK9 that binds to and breaks down these receptors, The antibodies in the tested drug, evolocumab are designed to intercept PCSK9, preventing the protein from breaking down the cells' LDL receptors, which allows them to stay in circulation longer to remove LDL cholesterol.